C

Crinetics Pharmaceuticals
D

CRNX

84.720
USD
0.03
(0.03%)
Pre Open·84.700USD-0.020(-0.02%)
Volume
13,176
EPS
-5
Div Yield
-
P/E
-17
Market Cap
8,989,446,720
Overview
Related Instruments
ALNY
ALNY
D
238.340
8.940(3.90%)
229.060-9.280(-3.89%)
BMY
BMY
D
67.380
1.890(2.89%)
65.430-1.950(-2.89%)
GILD
GILD
D
147.150
3.680(2.57%)
143.620-3.530(-2.40%)
LLY
LLY
D
1,264.25
19.01(1.53%)
1,226.39-38.67(-3.06%)
MRK
MRK
D
152.010
2.920(1.96%)
148.500-3.590(-2.36%)
PFE
PFE
D
28.095
0.265(0.95%)
27.750-0.330(-1.18%)
REGN
REGN
D
841.17
14.33(1.73%)
829.17-12.00(-1.43%)
SNY
SNY
D
45.980
0.850(1.88%)
45.250-0.740(-1.61%)
VRTX
VRTX
D
550.61
10.62(1.97%)
545.36-5.25(-0.95%)
More

Title: Crinetics Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
Smarter Decisions,Together
FacebookTwitterYoutubeLinkedIn
App Store
iOS
Google Play
Android

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.